Abstract

The Ki-67 labeling index (LI) is an important prognostic factor in breast carcinoma. The Ki-67 LI is traditionally calculated via unaided microscopic estimation; however, inter-observer and intra-observer variability and low reproducibility are problems with this visual assessment (VA) method. For more accurate assessment and better reproducibility with Ki-67 LI, digital image analysis was introduced recently. We used both VA and automated digital image analysis (ADIA) (Ventana Virtuoso image management software) to estimate Ki-67 LI for 997 cases of breast carcinoma, and compared VA and ADIA results. VA and ADIA were highly correlated (intraclass correlation coefficient 0.982, and Spearman’s correlation coefficient 0.966, p<0.05). We retrospectively analyzed cases with a greater than 5% difference between VA and ADIA results. The cause of these differences was: (1) tumor heterogeneity (98 cases, 56.0%), (2) VA interpretation error (32 cases, 18.3%), (3) misidentification of tumor cells (26 cases, 14.9%), (4) poor immunostaining or slide quality (16 cases, 9.1%), and (5) Estimation of non-tumor cells (3 cases, 1.7%). There were more discrepancies between VA and ADIA results in the group with a VA value of 10–20% compared to groups with <10% and ≥20%. Although ADIA is more accurate than VA, there are some limitations. Therefore, ADIA findings require confirmation by a pathologist.

Highlights

  • Breast cancer is one of the most frequent malignancies in women

  • The molecular classification of breast carcinomas can be confirmed according to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2), or Ki67 labeling index (LI) status

  • The characteristics of 964 patients and 997 tumors are summarized in Table 1, and all data is provided in S1 File

Read more

Summary

Introduction

Many studies have sought to improve treatment outcomes for breast cancer, and molecular studies play a critical role in prognosis. Measurement of Ki-67 labeling index in breast carcinomas leading to improvements in treatment, prognosis prediction, and outcomes. The molecular classification of breast carcinomas can be confirmed according to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2), or Ki67 labeling index (LI) status. In ER-positive and HER2-negative breast cancers in particular, the classification of subtypes is dependent on Ki-67 LI: tumors with low Ki67 LI are classified into the luminal A group and those with high Ki-67 LI into the luminal B group[5]. Recurrence rate, prognosis, and therapeutic recommendations differ according to subtypes

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.